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Abstract
Background: Diagnosis of West Nile virus (WNV) infections is often difficult due to the extensive antigenic cross-
reactivity among flaviviruses, especially in geographic regions where two or more of these viruses are present
causing sequential infections. The purpose of this study was to characterize a panel of monoclonal antibodies
(MAbs) produced against WNV to verify their applicability in WNV diagnosis and in mapping epitope targets of
neutralizing MAbs.
Methods: Six MAbs were produced and characterized by isotyping, virus-neutralization, western blotting and MAb-
epitope competition. The MAb reactivity against various WNVs belonging to lineage 1 and 2 and other related
flaviviruses was also evaluated. The molecular basis of epitopes recognized by neutralizing MAbs was defined
through the selection and sequencing of MAb escape mutants. Competitive binding assays between MAbs and
experimental equine and chicken sera were designed to identify specific MAb reaction to epitopes with high
immunogenicity.
Results: All MAbs showed stronger reactivity with all WNVs tested and good competition for antigen binding in
ELISA tests with WNV-positive equine and chicken sera. Four MAbs (3B2, 3D6, 4D3, 1C3) resulted specific for WNV,
while two MAbs (2A8, 4G9) showed cross-reaction with Usutu virus. Three MAbs (3B2, 3D6, 4D3) showed
neutralizing activity. Sequence analysis of 3B2 and 3D6 escape mutants showed an amino acid change at E307 (Lys
® Glu) in the E protein gene, whereas 4D3 variants identified mutations encoding amino acid changed at E276
(Ser ® Ile) or E278 (Thr ® Ile). 3B2 and 3D6 mapped to a region on the lateral surface of domain III of E protein,
which is known to be a specific and strong neutralizing epitope for WNV, while MAb 4D3 recognized a novel
specific neutralizing epitope on domain II of E protein that has not previously been described with WNV MAbs.
Conclusions: MAbs generated in this study can be applied to various analytical methods for virological and
serological WNV diagnosis. A novel WNV-specific and neutralizing MAb (4D3) directed against the unknown
epitope on domain II of E protein can be useful to better understand the role of E protein epitopes involved in the
mechanism of WNV neutralization.
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Background
West Nile virus is an arbovirus member of the Japanese
Encephalitis virus (JEV) serocomplex of the genus Flavi-
virus of the Flaviviridae family. WNV infection is one of
the most widespread arboviral infections and can cause
encephalitis in humans. Its transmission cycle involves
mosquito-vectors (mainly Culex spp.) and birds as
amplifying reservoirs, but a wide variety of vertebrate
species, including reptiles, amphibians and mammals,
such as equines and humans, are also susceptible to
infection [1].
The WNV genome is made up of a single stranded
positive-sense RNA molecule that encodes three struc-
tural proteins (capsid (C); pre-membrane (prM); and
envelope (E)) and seven non-structural proteins (NS1,
NS2A, NS2B, NS3, NS4A, NS4B, NS5) [2]. The envelope
E protein is the major surface protein of flaviviruses and
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the primary immunogen that plays a central role in
virus attachment and entry into a cell via membrane
fusion [3]. Crystallographic analysis reveals that the E
glycoprotein of flaviviruses folds into three distinct
structural domains (I, II and III) [4-6]. In particular,
domain III of WNV E protein (DIII) is the putative
receptor-binding domain and is an important target for
neutralizing antibodies and in vivo protection [7-11].
The recent outbreaks of West Nile Disease in humans
and horses in Europe and the spread of the virus from
North through South America during the last decade
suggest that the epidemiology of this infection is evol-
ving. In the Mediterranean basin, outbreaks of WNV
infection in recent years have been reported in France
(2004 and 2006), Italy (2008, 2009) Morocco (2010),
Spain (2010) and Greece [12]. WNV was previously con-
sidered an exotic agent, while it is now regarded as an
emerging problem for both human and veterinary public
health. These outbreaks have stimulated research into
virus detection and characterization, underlining the
need for rapid assays. Although many methods have
been developed for WNV diagnosis, it is commonly dif-
ficult due to the extensive antigenic cross-reactivity
among flaviviruses, especially in geographic areas where
two or more of these viruses are present causing
sequential infections [13]. It has recently been shown
that WNV and Usutu virus (USUV) have similar trans-
mission cycles, with overlapping geographic distributions
[14,15]. In this context, MAbs having strong and specific
reactivity to WNV antigens are the most suitable choice
for the development of standardized diagnostic tools.
The purpose of this study was to characterize a panel
of monoclonal antibodies produced against WNV to
verify their applicability in WNV diagnosis and in map-
ping epitope targets of neutralizing MAbs.
The results suggest the applicability of these MAbs to
various analytical methods for WNV diagnosis allowing
the characterization of a novel WNV-specific and neu-
tralizing epitope located on DII of E protein that has
not previously been described with WNV MAbs.
Results
Selection and characterization of monoclonal antibodies
During the screening phase of hybridomas, several
MAbs that were reactive to the WNV antigen were
obtained. Six hybridomas (3B2, 3D6, 1C3, 4D3, 2A8,
4G9) showing a strong signal with indirect ELISA and
immunofluorescence (IF) against homologous WNV
were selected and cloned by limiting dilution to ensure
monoclonality and stability. Positive clones that secreted
a high titer of selected antibodies were further identified
and MAbs were efficiently purified by protein-A chro-
matography and conjugated with horseradish peroxidase
(HRP). The general characteristics of selected anti-WNV
MAbs are summarized in Table 1.
All six MAbs showed good reactivity with Immuno-
peroxidase Monolayer Assays (IPMA) staining on all the
eight WNVs tested. Four MAbs 3B2, 3D6, 4D3 and 1C3
resulted WNV-specific without any cross-reaction to
USUVs and Tick-borne encephalitis virus (TBEV), and
three of these (3B2, 3D6, 4D3) showed neutralizing
activity at the same titers against both the homologous
WNV Eg101 and the prototype lineage 2 WNV B956.
MAbs 2A8 and 4G9 showed cross-reaction with the two
USUVs tested, but not with TBEV. No neutralizing
activity was observed. The heavy chain subclasses were
determined as IgG2a for all MAbs with the exception of
4D3, which was determined as IgG2b. The light chains
of all of these were kappa isotype.
Two MAbs (3B2, 3D6) resulted positive at western
blotting (WB), revealing a band with a molecular weight
of 52Kd corresponding to E protein. The remaining
MAbs did not recognize denatured WNV antigen at
WB, suggesting that they are all directed to conforma-
tional-dependent epitopes (Figure 1A). Figure 1B shows
IPMA assays performed with WNV, USUV and MAbs
3B2 and 2A8.
None of the MAbs showed any cross-reaction against
Dengue virus serotype 1, 2, 3 and 4 (DENV 1, 2, 3, 4),
Yellow fever virus (YFV), TBEV and Japanese Encephali-
tis virus (JEV) by indirect ELISA.
Competition binding ELISAs for MAb epitope studies
To determine if the selected MAbs would bind to over-
lapping epitopes, we tested MAbs using competitive
Table 1 Properties of selected anti-WNV MAbs
MAbs IPMA VNT WB Isotype




3B2 + - - 12800 12800 52
Kd
IgG2a
3D6 + - - 12800 12800 52
Kd
IgG2a
4D3 + - - 1600 1600 - IgG2b
1C3 + - - < 20 < 20 - IgG2a
2A8 + + - < 20 < 20 - IgG2a
4G9 + + - < 20 < 20 - IgG2a
IPMA: Detection of WNVs, USUVs and TBEV infected Vero cells by
immunoperoxidase assay. WNVs used are: Eg101, B956 ATCC, NY99 ATCC,
Central African Republic 1967, 203204/08, 225677/09, 208659/09, 204913/09.
USUVs used are: SAAR 1776, Vienna 2001-blackbird and 200092/2010. TBEV
used is 103457/09. + indicate reactivity against all viral strains tested, -
indicate absence of reactivity with all viral strains.
VNT: Virus neutralization against WNV Eg101 and WNV B956. Neutralizing
titers are calculated as reciprocal of MAb dilution producing 100% reduction
of CPE. MAbs were used as ascites fluid.
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binding ELISAs. For these studies, the saturating con-
centrations of unlabeled MAbs were incubated with par-
tially purified WNV antigen bound to the ELISA plates,
after which an HRP-conjugated “competitor” MAb was
added. If preincubation of the antigen with an unlabeled
MAb blocked subsequent binding of a conjugated MAb,
we concluded that MAbs bind to similar or at least
overlapping epitopes. The optimal dilution of each
HRP-conjugated MAb was determined by testing serial
two-fold dilution in WNV-coated ELISA plates and
selecting this as the working dilution to generate an
optical density of around 1.5. The selected working
A
B 1) 2) 
3) 4) 
Figure 1 (A) Western blot analysis. Reactivity of six anti-WNV MAbs with denatured antigen. A MAb against influenza virus was used as
negative control. M: protein molecular weight markers. Lane 1: sera from WNV infected horse. Lane 2: sera from WNV vaccinated horse. Lane 3:
sera from WNV negative horse. (B) Detection of WNV and USUV-infected cells using IPMA (10X). WNV-infected Vero cells stained with MAb
3B2 (1) and 2A8 (2). USUV-infected VERO cells stained with MAb 3B2 (3) and 2A8 (4).
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dilution was 1/8000 for MAb 3B2, 1/16000 for MAbs
3D6, 2A8, 4G9 and 1/4000 for 4D3, 1 C3. The results of
competitive ELISAs are reported in Table 2.
HRP-conjugated 3B2 inhibited the binding of 3D6 to
the antigen and vice versa, showing that 3B2 and 3D6
recognized overlapping epitopes. 4D3 and 1 C3 did not
significantly compete with any of the other MAbs tested
in this assay, which meant that 4D3 and 1 C3 recog-
nized two distinct epitopes different from 3B2, 3D6,
2A8 and 4 G9. HRP-conjugated 2A8 inhibited the bind-
ing of 4G9 to the antigen and vice versa, indicating that
2A8 and 4G9 recognized overlapping epitopes.
One-way partial competition observed for some MAbs,
as for 4D3 HRP, could be due to antibody-induced confor-
mational changes in E protein upon antibody binding or
steric hindrance. MAbs were thus categorized into four
groups. MAbs binding to the same epitopes or overlapping
epitopes were put into the same group, while non-compet-
ing MAbs were grouped individually (Table 2). Group one
consisted of MAbs 3B2 and 3D6, group two included
MAb 1 C3, group three included MAb 4D3 and group
four consisted of MAbs 2A8 and 4G9.
Antigen capture ELISA (AC-ELISA)
All possible combinations of trapping and conjugated
MAbs were evaluated to establish a sensitive AC-ELISA
for WNV detection. Each pair of MAbs was able to detect
all WNVs when used in sandwich ELISA without signifi-
cant differences in sensitivity. No reactivity to TBEV was
observed while pairs of MAbs formed by 2A8 and 4 G9
allowed the detection of USUVs (data not shown). Good
WNV-specificity combined with the highest signal was
obtained using 3B2 both as capture antibody and HRP-
conjugated as detector antibody. To determine the detec-
tion limit of AC-ELISA, serial dilutions of WNV Eg101
culture supernatant (105.1 TCID50/100 μl) were used to
construct the binding curve (Figure 2). An uninfected cell
culture supernatant was used as negative control. Accord-
ing to the cut-off threshold, calculated as the mean of
optical density (OD) of negative control plus two standard
deviations, the detection limit for the WNV AC-ELISAs
was deduced to be 10 3.8 TCID50/100 μl.
Competitive binding assays with experimental sera
This experiment was designed to evaluate the capability
of known experimental sera to inhibit the binding of
anti-WNV MAbs to the antigen and then to verify the
possibility of using them in competitive ELISA tests for
serological diagnosis in various animal species.
Sera from SPF chickens experimentally infected with
WNV and equine sera immunized using inactivated vac-
cine were tested in competitive ELISAs with each HRP-
conjugate MAb at a predetermined dilution. The results,
expressed as percent inhibition of MAb binding by com-
petition with serum antibodies, are shown in Table 3.
Good competition for antigen binding between all
MAbs and sample sera collected from vaccinated horse,
as well as infected chicken, was observed.
Escape mutant analysis for MAb epitope mapping
To identify residues that might define epitopes recog-
nized by the neutralizing monoclonal antibodies, poten-
tial neutralization-resistant escape mutants (EM) were
selected by growing WNV Eg101 in Vero cells in the
presence of MAbs 3B2, 3D6 and 4D3.
Four or five neutralization-resistant escape mutants were
identified for each MAb. Virus neutralization assays
showed that 3B2 and 3D6 were unable to neutralize both
EM3B2 and EM3D6, but retained strong neutralizing
activity against EM4D3. On the contrary, MAb 4D3 was
unable to neutralize EM4D3, but retained strong neutraliz-
ing activity against both EM3B2 and EM3D6. Comparative
sequence analysis of viral genome corresponding to E
genes of escape mutants and wild-type WNV Eg101 was
performed. A similar single-nucleotide mutation was iden-
tified on the E-protein genes of both EM3B2 and EM3D6
at residue 919 (AAG ® GAG) encoding an amino acid
change at E307 (Lys® Glu). Various nucleotide mutations
Table 2 Results of competition binding ELISAs for MAb epitope studies
Unlabelled MAbs HRP-conjugated MAbs
3B2 HRP 3D6 HRP 1C3 HRP 4D3 HRP 2A8 HRP 4G9 HRP
Group 1 3B2 4 6 85 64 90 80
3D6 4 5 86 65 87 75
Group 2 1C3 87 95 7 60 75 60
Group 3 4D3 85 93 91 5 88 72
Group 4 2A8 95 100 84 65 4 4
4G9 92 100 84 63 4 3
no MAb 100 100 100 100 100 100
Result expressed as percent binding of HRP-conjugated MAbs. The amount of binding obtained in the absence of unlabeled antibody was set at 100% for each
HRP conjugated MAb. First column indicates the group assignments of MAbs based on competition binding assay. MAbs binding to overlapping epitopes are
grouped together, while non-competing MAbs are grouped individually.
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were identified on the E-protein gene of EM4D3 at residue
827 (AGC ® ATC) encoding an amino acid change at
E276 (Ser® Ile) or at residue 833 (ACT® ATT) encod-
ing an amino acid change at E278 (Thr® Ile). Tridimen-
sional macromolecular structure of E protein showing
these amino acid residues are reported in Figure 3. None
of these mutations was associated with measurable differ-
ences for growth in cell cultures.
Based on the sequence of in vitro neutralization
escape variants, MAb 3B2 and 3D6 map to a region on
the lateral surface of DIII, which has been previously
described as an important neutralizing epitope for WNV
[7,16], while MAb 4D3 appears to recognize a novel
neutralizing epitope on DII that has not previously been
described with WNV MAbs.
Discussion
West Nile virus is not only a human pathogen, but is
also a major veterinary pathogen. One of the principal
factors preventing the development of clinical disease
Figure 2 Sensitivity of AC-ELISA using MAb 3B2 and WNV cell culture supernatant. Detection limit from 200- to 300-fold dilution of cell
culture supernatant which was 103,8TCID50/0,1 ml. The broken line indicates the absorbance ratio cut-off value.
Table 3 Percent inhibition of WNV-reactive MAb binding with competitive ELISA using sera from WNV-infected
chicken and WNV-vaccinated horse during period between infection and serum collection
Days post-infection/vaccination WNV VN titer % Inhibition of MAb binding
3B2 3D6 4D3 1C3 2A8 4G9
Chicken 0 < 5 0 4.7 ± 2.1 4.7 ± 1.5 8 ± 2 7 ± 1.2 4.3 ± 1.5
7 10 56.7 ± 2.1 76.7 ± 2.1 43.3 ± 2.5 79 ± 4.6 75.7 ± 1.5 75 ± 3.5
15 20 77 ± 1 80.3 ± 2.1 78.7 ± 2.5 86.7 ± 1.2 87 ± 2.6 91.7 ± 1.5
24 40 81 ± 2.6 80 ± 1.7 83.7 ± 1.5 89.3 ± 1.2 89 ± 1 94.3 ± 0.6
42 160 92.7 ± 1.5 95.3 ± 0.6 91 ± 1 93.7 ± 1.2 95.7 ± 1.2 94.3 ± 1.5
Horse 0 < 5 28.7 ± 2.1 15.7 ± 2.1 47.3 ± 2.5 19 ± 1 23.7 ± 1.5 23.3 ± 2.5
15 < 5 71 ± 2 42.3 ± 1.2 73 ± 1 42.7 ± 0.6 44 ± 1 64.3 ± 1.5
21 10 81.7 ± 1.5 65 ± 1 74.7 ± 0.6 69.3 ± 3.5 65.7 ± 1.5 80.3 ± 2.1
28 20 88.7 ± 0.6 71.7 ± 1.5 85.7 ± 1.5 78.7 ± 1.2 77 ± 2 88.3 ± 0.6
31 (2°v) 80 95.7 ± 0.6 92.7 ± 1.5 91.3 ± 1.2 91.7 ± 1.5 93.3 ± 3.1 95 ± 1
MAbs were tested in triplicate. All sera were diluted 5 fold.
Values are mean ± standard deviations.
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due to WNV infection is the presence of protective neu-
tralizing antibodies. However, despite much progress,
many unanswered questions remain concerning WNV
neutralization mechanisms.
The majority of potent murine neutralizing MAbs
described to date against WNV bind to domain III, more
specifically to an epitope on the lateral surface of DIII
recognized by specific antibodies with the strongest neu-
tralizing activity in vitro and in vivo [7,9,10,16,17]. In this
study, six monoclonal antibodies produced against WNV
lineage 1 were characterized and their applicability in
laboratory diagnosis was assessed. Furthermore, through
selection of neutralizing-MAb escape mutants, we
defined the molecular basis of two epitopes recognized
by our neutralizing MAbs.
We showed that all six MAbs (3B2, 3D6, 4D3, 1C3,
2A8, 4G9) had strong reactivity in IPMA for all the eight
WNVs tested, including reference strains belonging to
lineages 1 and 2 as well as field strains isolated during
the Italian epidemics. This finding suggests that all MAbs
recognized conserved regions among WNVs. We also
showed the cross-reactivity of 2A8 and 4G9, which
recognize the overlapping epitopes shared between WNV
and USUV while no MAbs exhibited any cross-reactions
with other related flaviviruses tested. Considering that
WNV, USUV and TBEV are the flaviviruses currently cir-
culating in Europe, a good knowledge of MAb reactivity
against them is very important for their implementation
as diagnostic tools.
MAbs 3B2, 3D6 and 4D3 neutralized lineage 1 and
lineage 2 WNV. Moreover, they neither neutralized nor
recognized USUV and TBEV. MAb-binding sites of neu-
tralizing MAbs have been characterized by the selection
and sequencing of MAb escape mutants. We showed
that 3B2 and 3D6 recognized the same epitopes located
on the distal lateral surface of DIII. Specifically,
sequence analysis of 3B2 and 3D6 escape variants
showed a single-nucleotide mutation in the E protein
gene that encodes an amino acid change at E307 (Lys
® Glu). This residue defines an epitope that has pre-
viously been described as an important epitope recog-
nized by WNV-specific antibodies with the strongest
neutralizing activity [7,9,10,16,17]. Recent studies report
that recombinant DIII peptides containing virus-specific
epitopes could be used for specific serological diagnosis
of flaviviral infections [18-20]. Considering the extensive
antigenic cross-reactivity among flaviviruses, we specu-
lated that joining recombinant DIII peptides to anti-DIII
MAbs such as 3B2 and 3D6 for the development of ser-
ological tests for WNV diagnosis could provide good
results as regards specificity. Additionally, Oliphant et
al. (2005) showed that MAbs against WNV-DIII have
therapeutic potential against this virus, while DIII E
peptides could be used as subunit flavivirus vaccines
[18,21-23].
Numerous studies on neutralizing monoclonal antibo-
dies outside DIII have been reported [24-27]. We saw
that MAb 4D3 recognized a neutralizing epitope on
domain II that is a JEV complex epitope, already seen in
other studies [28] but which has not been previously
described in WNV. Nucleotide mutations were identi-
fied on the E gene of 4D3 variants encoding amino-acid
changes at E276 (Ser ® Ile) or E278 (Thr ® Ile). The
WNV inhibiting role of this specific neutralizing epitope
located on DII needs further investigation to verify its
role as a candidate for the development of diagnostic
E307 
E276, E278 
Figure 3 3D macromolecular structure of WNV E protein based on the crystal structure available in Molecular modelling database
(PDB: 2I69-A) visualized by Cn3D version 4.3. Mutated amino acid residues important for MAbs binding 3B2, 3D6 (E307) and 4D3 (E276,
E278) are evidenced in yellow.
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tools, as well as for use as an antiviral vaccine and for
therapeutics. The mechanisms of neutralization and the
role of the different epitopes of the WNV envelope pro-
tein have not been fully understood. According to San-
chez et al. [29], the neutralizing response to WNV
generated in infected horses is both variable and poly-
clonal in nature, with epitopes both within and outside
DIII playing important roles. The same study reports
that in some horses that were naturally infected with
WNV, antibodies directed against DIII epitopes were
not consistently detected, and DII may be an important
target for neutralizing antibodies in these animals. The
anti-domain II MAb 4D3 could be used in competitive
tests, in parallel to MAbs directed against DIII, to reveal
WNV-neutralizing antibodies in animal species. This is
supported by our results obtained with competitive ELI-
SAs designed using experimental horse and chicken sera
and HRP-conjugated MAbs. Good competition for anti-
gen binding between MAb and sample sera from vacci-
nated horse, as well as infected chicken, was observed.
Additionally, good competition was also observed in
competitive ELISAs between 3B2, 3D6 and infected
horse sera collected during the WNV Italian epidemics
(data not shown). These results also indicate that all
MAbs herein described react to epitopes with high
immunogenicity and that they could be used for the
development of competitive tests for the detection of
different types of anti-WNV antibodies in animal spe-
cies, e.g. WNV-specific and neutralizing antibodies
directed to DIII (MAbs 3B2 and 3D6) or DII (MAb
4D3), WNV-specific non-neutralizing antibodies (Mab
1C3) or flavivirus cross-reactive non-neutralizing antibo-
dies (MAbs 2A8 and 4 G9).
The availability of MAbs with strong reactivity to WNV
is also a crucial component for AC-ELISA development
usable for large-scale screening in surveillance programs.
Various MAb combinations were evaluated for WNV
detection using AC-ELISA. It was found that a combina-
tion of 3B2 as catcher and tracer MAb gave the highest
signal combined with good specificity. The detection
limit of 103.8TCID50/100 μl for WNV-infected cell cul-
ture supernatant obtained in the present study is com-
parable with that found in previously published AC-
ELISA [30]. Considering that AC-ELISAs performed with
pairs of MAbs made up of 2A8 and 4G9 allowed the
detection of USUVs, these tests could be useful for viral
detection in pathological specimens or cell cultures in
areas where WNV and USUV spread concomitantly.
Conclusions
Six MAbs against WNV were produced and character-
ized. The results suggest the applicability of these MAbs
to various analytical methods for antigen or antibody
detection in areas such as the Mediterranean basin,
where there is contemporary circulation of WNV,
USUV and TBEV. Additionally, in this study the novel
WNV-specific neutralizing MAb 4D3 directed against
the unknown epitope on domain II of the E protein of
WNV was generated and characterized.
Materials and methods
Viruses
The virus used in this study as an immunogen for MAb
production was the WNV reference strain Eg101.
Other WNVs used in this study included: B956
ATCC, NY99 ATCC, Central African Republic 1967,
203204/08 isolated from magpies (Pica pica) during the
2008 Italian epidemic and three other Italian field
strains (225677/09, 208659/09, 204913/09) isolated in
our lab in 2009 from a jay (Garrulus glandarius), a
horse and mosquitoes (Culex pipiens) respectively.
Other flaviviruses used included three strains of USUV,
reference strain SAAR 1776, Vienna 2001-blackbird and
200092/2010 (Italian field strain isolated in our lab from
a blackbird), and TBEV strain 103457/2009 (Western
TBEV group) isolated in our lab from the brain of dog
that had been in an endemic area (Hungary) for a short
period in April 2009. Virus stocks were prepared in
Vero cells that were cultured at 37°C with 5% CO2 in
minimum essential medium (MEM) containing 10% of
fetal serum bovine, 0.1 mM of nonessential amino acids,
0.15% sodium bicarbonate, 2 mM L-glutamine, penicillin
(100 U/ml) and streptomycin (100 μg/ml). Virus titers
were determined by endpoint assays in Vero cells.
Antigen preparation
For its use as an immunogen for MAb production in
Balb/c mice and for the preparation of ELISA coating
antigen, WNV Eg101 was partially purified as follows.
WNV was grown on a preformed monolayer of Vero
cells and incubated at 37°C until the cytopathic effect
(CPE) is complete. After a freeze-thaw step, virus inacti-
vation was carried out by the addition of 0.05% (v/v)
Betapropiolactone to the culture fluids, followed by
incubation at 37°C for 2 h plus overnight incubation at
4°C. Virus inactivation in the culture fluid was verified
following three blind passages in Vero cell monolayers
without CPE development. Inactivated supernatant fluid
was clarified by centrifugation at 4000 rpm for 30 min,
added to 8% of PEG 6000 and NaCl 0.5 M then placed
overnight at 4°C in agitation. The suspension was centri-
fuged at 5000 rpm for 30 min and the pellet was re-sus-
pended in phosphate-buffer saline solution pH 7.4 (PBS)
at 20X concentration compared to the initial volume.
Following further clarification by centrifugation (5000
rpm for 30 min), the viral suspension was purified by
ultracentrifugation at 35000 rpm for 2 h (rotor TST41
Kontron) through a 25% (w/w) sucrose cushion and the
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pellet was re-suspended in PBS. This concentrated anti-
gen was kept at -70°C until use.
Experimental sera production
Immune chicken sera
Five SPF chickens were used. Three of these (positive
control) were experimentally infected intramuscularly
with 1 ml containing 106.5TCID50 of WNV Eg101
grown on BHK21, while the remaining two chickens
(negative control) were injected intramuscularly with a
cell suspension of BHK21. Blood samples were taken 7,
15, 24, 42 days post-infection.
Immune horse sera
Two ponies tested seronegative for WNV using a virus
neutralization test were vaccinated intramuscularly with
2 doses of commercial inactivated vaccine. Thirty-five
days after the first vaccination, a second immunization
with two additional doses was performed. Blood samples
were taken 15, 21, 28 days after the first vaccination and
31 days after the second vaccination.
Animal care and all procedures were performed in
accordance with guidelines and regulations of the Italian
animal protection laws and under EC policy related
issues (D.L. 116/1992 amending Dir. CEE n. 609/86).
Monoclonal antibody production
Two Balb/c mice were primed subcutaneously with 50 μg
of Betapropiolactone-inactivated WNV with complete
Freund’s adjuvant and boosted intraperitoneally with the
same antigen in PBS (phosphate-buffered saline pH 7.4)
once or twice at one month intervals of one month.
Three days after the last boost, the mice were sacrificed
and hybridomas were generated following fusion of sple-
nocytes with NS0 myeloma cells and selected cultures
were grown following the standard procedure [31].
Hybridomas were screened for secretion of desired anti-
bodies with indirect ELISA using the homologous WNV
and IF with infected and non-infected Vero cells. Positive
hybridoma cells were cloned using limiting dilution to
obtain antibodies from a single cell. Hybridoma culture
supernatants or ascitic fluids harvested after in vivo cul-
ture of hybridoma were used as a MAb source. MAbs
were purified from ascites using affinity chromatography
through protein A Sepharose (Pharmacia, Milan, Italy) in
the presence of 3 M Nacl and 1.5 M glycine pH 8.9 [32],
and conjugated with HRP using a modified form of the
method described by Tjissen and Kurstak 1984 [33]. The
immunoglobulin subclass was determined using a Mouse
Immunoglobulin Isotyping ELISA kit (BD Pharmingen)
following the manufacturer’s instructions.
Immunofluorescence (IF)
Confluent monolayers of Vero cells grown in 96-well
microplates were infected with 100TCID50 of WNV
Eg101. After incubation for 48/72 hours at 37°C, or fol-
lowing the appearance of a mild cytopathic effect,
infected cells were fixed in acetone for 1 h at -20°C,
dried and incubated with hybridoma supernatants at 1:2
dilution in PBS for 1 h at 37°C. Cells were washed with
PBS before a 30-min incubation with FITC-labeled goat
anti-mouse immunoglobulin (produced in-house). The
cells were washed again, stained with Evans Blue and
observed using fluorescence microscopy. Cells showing
a strong green fluorescent signal were recorded as posi-
tive. The uninfected cells were used as a negative
control.
ELISAs
All ELISAs were performed in 96-well Nunc Maxisoarp
ELISA plates.
Indirect ELISAs
For hybridoma screening, ELISA plates were coated with
50 μl per well of partially purified WNV antigen (pro-
duced as previously described) at saturating concentra-
tion by incubation overnight at 4°C in ELISA coating
buffer (0.05 M carbonate/bicarbonate buffer pH 9.6).
Plates were washed three times with 250 μl of wash buf-
fer (PBS containing 0.05% Tween 20) with an automatic
plate washer after which 50 μl of undiluted hybridoma
culture supernatants were added to each well and incu-
bated for 1 h at 37°C. After three washes, an HRP-con-
jugated goat anti-mouse immunoglobulin antibody
(produced in-house) was added at dilution 1/500 in dilu-
tion buffer (PBS with 0.05% Tween 20 and 1% yeast
extract) to each well and incubated again for 1 h at 37°
C. After a final wash cycle, 50 μl of substrate solution
(orthophenylenediamine 0.5 mg/ml and 0.02% H2O2 in
50 mM phosphate citrate buffer pH 5) was added. After
10 min, the colorimetric reaction was stopped by the
addition of 2 N sulfuric acid; absorbance values were
read at 492 nm using an ELISA reader.
To investigate the MAbs-specificity, the reactivity of
all MAbs was evaluated against TBEV, DENV1, DENV
2, DENV 3, DENV 4, YFV, JEV by indirect ELISAs.
Competitive binding assays for MAb epitope studies
Competition binding ELISAs were performed in WNV-
coated immunoplates. Fifty microliters of unlabeled
hybridoma culture supernatants were added at saturat-
ing dilution. After incubation for 15 min at 37°C, 25 μl
of HRP-conjugated “competitor” MAb was added at
pre-determined optimal dilution (which had given an
absorbance value of 1-1.5 in a preliminary titration)
without washing and incubated again for 1 h at 37°C.
Follow a final wash cycle, 50 μl of substrate and stop-
ping solution were added and absorbance values were
determined as previously described. Wells without the
addition of unlabeled MAb were used as negative con-
trol and wells with the addition of unlabeled MAb (the
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same as the HRP-conjugated MAb) were used as a posi-
tive control. Results were expressed as percent binding
of HRP-conjugated MAb. The amount of binding
obtained in the absence of unlabeled antibody was set at
100% for each HRP-conjugated MAb.
Competitive ELISA with experimental sera
Competitive ELISAs were designed to analyze the cap-
ability of known experimental horse and avian sera to
inhibit the binding of anti-WNV MAbs to the antigen.
Fifty microliters of known sera, at sequential dilutions
starting from 1/5, were incubated for 1 h at 37°C in
WNV-coated immunoplates, together with 25 μl of
HRP-conjugated MAb at the pre-determined optimal
dilution. After washes, the colorimetric reaction was
achieved as previously described and absorbance values
at 492 nm determined. The optical density (OD) of each
well was converted to the percent of inhibition (PI) of
MAb binding by competition with serum antibodies
using the following formula: PI = [1-(OD of serum-Mab
mixture/OD of Mab alone)] × 100.
Antigen capture-ELISA (AC-ELISA)
ELISA plates were coated with purified MAbs at a con-
centration of 10 μg/ml and incubated overnight at 4 C
in ELISA coating buffer. Fifty microliters of WNV-
infected culture supernatants (listed above) at sequential
dilutions were added to each well and plates were incu-
bated for 1 h at 37°C. After washes, 50 μl of HRP-conju-
gated MAb at a pre-determined dilution was added and
incubated again for 1 h at 37°C, followed by a final wash
cycle. Diluting buffers, washing and colorimetric reac-
tions were the same as for the ELISAs previously
described. Several combinations of trapping and conju-
gated MAbs were tested. Uninfected cell culture super-
natants were used as a negative control, and USUV and
TBEV-infected culture supernatants were used to evalu-
ate the specificity. The cut-off OD was calculated as the
mean OD of negative samples plus two standard
deviations.
Western blotting (WB)
Western blotting was performed using a standard proto-
col [34]. Briefly, SDS and b mercaptoethanol denatured
WNV-antigen protein were separated on 12% SDS-
PAGE [35] and transferred to nitrocellulose filters [36].
MAb tissue cultures were diluted 1/5 in a phosphate sal-
ine buffer at pH 7.2 containing 1% w/v of bovine albu-
min and 0.05% w/w of Tween 20. MAb binding was
detected by incubation with alkaline phosphatase-labeled
rabbit anti-mouse IgG, and the chromogenic substrate
5-bromo-4-chloro-3-indolylphosphate-Nitro Blue
Tetrazolium (BCIP/NBT). Horse sera were diluted 1/
200 in the phosphate buffer described above. Antibody
binding was detected by incubation with an HRP-labeled
goat anti-horse IgG and the chromogenic substrate 4-
Chloronaphthol (4CN).
Immunoperoxidase (IPMA)
IPMA was used to evaluate the reactivity profile of
MAbs with all flaviviruses used in this study and pre-
viously described. Infected monolayers of Vero cells on
96-well microplates were prepared for each virus as
described for IF. IPMA plates were filled with PBS with
20% of H2O2, dried and incubated with 100 μl of MAbs
at 1:2 and 1.4 dilution in PBS for 1 h at 37°C. Cells
were washed 3 times with PBS, after which 100 μl of
HRP-conjugated goat anti-mouse IgG was added to each
well and plates were incubated for 1 h at 37 C. After 3
further washings, substrate (5 mg/ml of 3-amino-9-
ethylcarbazole in dimethyl sulfoxide) diluted in 0.05 M
AEC buffer pH 5.2 (105 ml 0.2 M acetic acid, 395 ml
0.2 M sodium acetate, and 500 ml distilled water) was
added. The colour reaction was allowed to develop for
20 minutes and the plates washed once with PBS and
then examined under a light microscope. The uninfected
cells were used as a negative control for each MAb
dilution.
Virus-neutralization test (VNT)
The competence of MAbs to neutralize virus infectivity
was investigated by VNT carried out in 96-well micro-
plates using two different strains of WNV in parallel
(Eg101, B956), belonging respectively to lineages I and II
and Vero cells. Serial twofold dilutions of MAbs (2
wells/dilution) in 25 μl of serum-free culture medium
were added to each well and incubated for 1 h at 37°C
with an equal volume of tissue culture fluid containing
100 TCID50 of WNV. Virus back titration of the work-
ing dilution of virus is included, using six wells per ten-
fold dilution, to confirm the validity of the test results.
A volume of 50 μl of Vero cells at log5 cells/ml in med-
ium containing 10% fetal calf serum was added to each
well. After incubation for 72-96 hours at 37°C with 5%
CO2, wells were scored for cytopathic effect and neutra-
lizing titers were expressed as the reciprocal of the final
MAb dilution required to neutralize 100% of the inocu-
lated cultures.
Selection of neutralization escape mutants
Neutralization escape mutants were selected by growing
WNV in Vero cells in the presence of neutralizing
MAbs using a modification of the method described by
Holzmann et al., 1989 [37]. Essentially, serial 10-fold
dilutions of WNV Eg101 (107 TCID50/ml) were incu-
bated for 1 h at 37°C with an equal volume of ascites
fluid containing between 1 and 8 mg/ml of neutralizing
MAb. Aliquots of the virus-MAb mixture (100 μl) were
adsorbed to Vero cell monolayer in 24-well plates for 1
h at 37°C, after which fresh medium was added. After
incubation for 7 days at 37°C, samples of the superna-
tants showing CPE were screened for the presence of
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escape mutants by trapping ELISAs employing a non-
neutralizing MAb (flavivirus-cross-reactive) as catcher
and homologous neutralizing MAb in parallel with non-
neutralizing MAb (flavivirus-cross-reactive) as conjugate.
Mutants that were not recognized by homologous MAb
while maintaining reactivity with the non-neutralizing
MAb were selected and sub-cultured twice in the pre-
sence of ascites fluid. A fourth passage without MAb
was performed and presumptive mutants were harvested
when CPE was evident (48-72 h post-infection). Finally,
each selected escape variant was cloned by limiting dilu-
tion, and amplified in Vero cells for the preparation of
stock suspensions that were stored at -80°C and then
titrated. The escape capability from MAb neutralization
was investigated by virus neutralization tests performed
using 100 TCDI50 of WNV selected variants and serial
two-fold dilution of MAbs in Vero cells.
Sequence analysis
Viral RNA was extracted from wild-type WNV Eg101,
and WNV escape mutants using the Trizol reagent
(Invitrogen, Carlsbad, CA, USA) according to the manu-
facturer’s protocol. Regions of viral genome correspond-
ing to genes for structural protein E were amplified for
sequencing by reverse transcription-PCR [38]. One-step
RT-PCR Kit (Qiagen) was used to run conventional RT-
PCR assays, following the manufacturer’s instructions.
Amplification products were analyzed by electrophoresis
on 2% agarose gels containing 0.5 μg/ml ethidium bro-
mide. All fragments amplified by PCRs were sequenced
by an automated fluorescence-based technique using an
ABI-PRISM 3130 Genetic Analyzer (Applied Biosys-
tems), following the manufacture’s instruction. 3D
macromolecular structure of WNV E protein was per-
formed as described in Figure 3.
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